LX-9211

Lexicon Pharmaceuticals' non-opioid painkiller pilavapadin failed to achieve statistical significance versus placebo in Phase IIb RELIEF-DPN-1 trial for diabetic neuropathy pain.

Lexicon Pharmaceuticals' LX9211, a non-opioid therapy, completed Phase 2b trial for diabetic peripheral neuropathic pain, exceeding enrollment targets due to high interest.

Lexicon Pharmaceuticals will host a virtual webcast on January 28, 2025, featuring an in-depth discussion of LX9211, their investigational non-opioid treatment for diabetic peripheral neuropathic pain.

The FDA issued a Complete Response Letter for Lexicon's Zynquista (sotagliflozin) for type 1 diabetes and chronic kidney disease, marking its second rejection.

Lexicon Pharmaceuticals has finished enrolling 494 subjects in its Phase IIb PROGRESS trial, exceeding the initial target by 20%, to evaluate LX9211 for diabetic peripheral neuropathic pain (DPNP).